FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Healix Infusion Therapy BUPivacaine HCl 0 Recall

BUPivacaine HCl 0

Healix Infusion Therapy, Inc. · Sugar Land, TX

Risk level
Class II
Reported by FDA
Jul 16, 2014
Recall ID
D-1422-2014
Check your lot numberHow we source this data

Summary

Healix Infusion Therapy recalled BUPivacaine HCl 0 starting Feb 13, 2014. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1422-2014 on Jul 16, 2014. Reason: Presence of Particulate Matter: The bupivacaine HCl injection used to compound this lot of BUPivacaine HCl 0.25% Preservative Free 500 mL in On-Q C-bloc was recalled by the supplier due to a customer complaint of visible particles embedded in the glass vial. Status: Terminated.

Why it was recalled

Presence of Particulate Matter: The bupivacaine HCl injection used to compound this lot of BUPivacaine HCl 0.25% Preservative Free 500 mL in On-Q C-bloc was recalled by the supplier due to a customer complaint of visible particles embedded in the glass vial.

Product description

BUPivacaine HCl 0.25% Preservative Free (2.5 mg/mL) 500 mL in On-Q C-bloc (2-14 mL/hr) bag, Healix Infusion Therapy, Inc., 1075 West Park One Drive, Suite 200, Sugar Land, Texas 77478, NDC 75901-7210-53.

Lot numbers, UPCs & expiration codes

Lot #: 6156-0, Exp 03/07/14

Where it was sold

Texas

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1422-2014
Classification
Class II
Status
Terminated
Recall initiated
Feb 13, 2014
FDA report date
Jul 16, 2014
Quantity
10 bags
Recall type
Voluntary: Firm initiated
Recalling firm
Healix Infusion Therapy, Inc.

Original FDA data

Every field from FDA enforcement report D-1422-2014, exactly as published.

Show all FDA fields
City
Sugar Land
State
TX
Status
Terminated
Country
United States
Event ID
68304
Address
1075 W Park One Dr
Code information
Lot #: 6156-0, Exp 03/07/14
Postal code
77478-2576
Report date
Jul 16, 2014
Product type
Drugs
Recall number
D-1422-2014
Classification
Class II
Recalling firm
Healix Infusion Therapy, Inc.
Product quantity
10 bags
Termination date
Feb 16, 2016
Reason for recall
Presence of Particulate Matter: The bupivacaine HCl injection used to compound this lot of BUPivacaine HCl 0.25% Preservative Free 500 mL in On-Q C-bloc was recalled by the supplier due to a customer complaint of visible particles embedded in the glass vial.
Voluntary / mandated
Voluntary: Firm initiated
Product description
BUPivacaine HCl 0.25% Preservative Free (2.5 mg/mL) 500 mL in On-Q C-bloc (2-14 mL/hr) bag, Healix Infusion Therapy, Inc., 1075 West Park One Drive, Suite 200, Sugar Land, Texas 77478, NDC 75901-7210-53.
Distribution pattern
Texas
Recall initiation date
Feb 13, 2014
Initial firm notification
Letter
Center classification date
Jul 7, 2014

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1422-2014, published Jul 16, 2014. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls